Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
“We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression”
– Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer’s disease by identifying a new drug target for not only improving symptoms of brain degeneration – but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: “The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer’s disease.
“We have been using mice whose brain cells are progressively dying, similar to what happens in Alzheimer’s disease. This project focuses on a particular protein in the brain, which is proposed to be involved in Alzheimer’s disease, and as such could be a potential target for new drugs.
“We have treated mice with a new class of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice.”
The researchers state that drugs which activate this protein receptor in the brain have previously been tested in clinical trials for Alzheimer’s disease, and showed positive results with respect to improving cognition, but the patients experienced a large number of adverse side effects. This new class of drug is more selective and does not cause any side-effects when administered to mice in the study.
The study authors believe that this offers hope in the design of new drugs for improving cognition and extending life span.
Professor Tobin said: “This work may provide important information as to whether this protein is a viable drug target in the treatment of diseases associated with the progressive death of brain cells. This is of great importance to society, based on the fact that the treatment options for Alzheimer’s disease are very limited – there are no cures for Alzheimer’s disease and current treatments are focused on relieving some of the symptoms.
“What we have found is a novel class of drugs, called allosteric ligands, that target a protein called the M1 muscarinic receptor, which is present in the brain. Activating this receptor protein can not only improve cognitive function in mice with progressive brain degeneration, but when administered daily, can extend life span.”
The scientists say the work is important because it focuses on identifying a treatment that not only improves symptoms associated with neurodegeneration, like current treatments, but also identifies a new strategy for slowing disease progression and extending life-span.
Professor Tobin said: “Alzheimer’s disease is the most common form of dementia, and it affects an estimated 850,000 people in the UK alone. There are no treatments that can slow or halt the progression of Alzheimer’s, and patients are treated with drugs which temporarily mask the symptoms of the disease. Often these treatments are associated with side-effects which can limit patient compliance.
“I am proud to be involved in a collaboration with researchers across the world to address one of the world’s major healthcare challenges. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression.”
[osd_subscribe categories=’alzheimers’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “ALZHEIMERS”‘]
Receive an email update when we add a new ALZHEIMERS article.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Summerville artist uses talent to donate to Alzheimer's supporton May 18, 2022 at 5:00 am
A local mosaic glass artist who reads this column and I were in contact with each other in March. I recently visited her home studio so I could take several ...
- Alzheimer’s Disease and Daytime Napping Linked in New Researchon May 18, 2022 at 4:55 am
Longer and more frequent napping was correlated with worse cognition. Could there be a connection between cognitive decline and excessive daytime napping? New research from the Rush Alzheimer’s ...
- Alzheimer’s disease Diagnostic Market Size, Share, Trends, Business Strategies, Revenue, Leading Players, Opportunities and Forecast 2027on May 18, 2022 at 3:29 am
The Alzheimer’s disease Diagnostic Market Share is projected to increase at a faster rate in the near future. The Alzheimer’s Disease Diagnostic Market for this is expected to reach USD 12 billion by ...
- Lord Kinnock reveals Alzheimer’s toll on wife Baroness Kinnock of Holyheadon May 18, 2022 at 3:00 am
Lord Kinnock has spoken of his wife’s Alzheimer’s disease, revealing that she was given the diagnosis in 2017 and that they had help from carers each day. The former Labour leader, who has been ...
- Florida clinical trial shows promise in fighting Alzheimer's diseaseon May 17, 2022 at 7:27 pm
SLIPPING AWAY, OFTEN FORGETTING THINGSND A PEOPLE BECAUSE OF ALZHEIMER’S. JIM: THAT STORYLINE HITS HOME HARD FOR MILLIONS OF AMERICANS WHO CAN RELATE TO BEING ROBBED OF A LOVED ONE BECAUSE OF ETH ...
- Why Your Gut Could Be the Key to Preventing Anxiety, Alzheimer’s, and Moreon May 17, 2022 at 12:41 pm
But this common experience—your gut seeming to act out your brain’s anxiety—is an everyday example of fascinating new research into the interconnected worlds inside us. So, is your gut the key to a ...
- Alzheimer's, Cognitive Impairment Linked With Choroid Plexus Volumeon May 17, 2022 at 12:03 pm
Increased volume of the choroid plexus, which produces and secretes cerebrospinal fluid (CSF), was tied to cognitive impairment and Alzheimer's disease, a retrospective study showed. Among 532 adults ...
- Alzheimer’s Association says accelerated drug approvals necessary in search for treatmenton May 17, 2022 at 6:55 am
That decision has come under fire by Alzheimer's advocates such as Katherine Lambert, who heads the Alzheimer’s Association in the Carolinas and Georgia. She said that Medicare should pay for Aduhelm ...
- How Alzheimer's Disease and Other Dementias Differ, and How They're Misunderstoodon May 17, 2022 at 5:02 am
Depending on the diagnosis, dementia can turn families' lives upside down in many ways. Alzheimer's disease is the most common form of dementia. The Alzheimer's Association's 2022 Facts and Figures ...
via Bing News